BEAT · Heartbeam Inc. Common Stock
View on chartInsiders & Stakes
| Vajdic Branislav CHIEF EXECUTIVE OFFICER | ▲ Buy | Grant | 3,970,784 Shares held | 7/24/2026 | View profile |
| STROME MARK E 10% Owner | ▲ Buy | Open Market | 3,650,000 Shares held | 4/16/2026 | View profile |
| Elfrink Willhem Director | ▲ Buy | Open Market | 538,667 Shares held | 4/16/2026 | View profile |
| Persen Kenneth Harry Chief Technology Officer | ▲ Buy | Grant | 448,290 Shares held | 7/24/2026 | View profile |
| Richard Ferrari Director | ▲ Buy | Open Market | 291,636 Shares held | 4/16/2026 | View profile |
| Cruickshank Tim CFO | ▲ Buy | Grant | 239,990 Shares held | 7/24/2026 | View profile |
| Nelson Kenneth Warwick III Director | ▲ Buy | Grant | 144,388 Shares held | 2/9/2026 | View profile |
| Ortigas-Wedekind Marga Director | ▲ Buy | Open Market | 137,293 Shares held | 4/16/2026 | View profile |
| BROUNSTEIN RICHARD D CHIEF FINANCIAL OFFICER | ▲ Buy | Option Exercise | 112,108 Shares held | 2/10/2023 | View profile |
| ENO Robert Paul President | ▲ Buy | Open Market | 36,742 Shares held | 4/16/2026 | View profile |
| JAFF MICHAEL R Director | ▲ Buy | Open Market | 31,250 Shares held | 4/16/2026 | View profile |
| Hunt Jon Patrick Chief Business Officer | ▲ Buy | Option Exercise | 23,976 Shares held | 11/11/2021 | View profile |
| de Urioste George Director | ▼ Sell | Open Market | 0 Shares held | 12/18/2025 | View profile |
Transaction History
| Vajdic Branislav | ▲ Buy | Grant | 260,870 | $0 | 7/24/2026 |
| Persen Kenneth Harry | ▲ Buy | Grant | 105,740 | $0 | 7/24/2026 |
| Cruickshank Tim | ▲ Buy | Grant | 167,760 | $0 | 7/24/2026 |
| Vajdic Branislav | ▲ Buy | Grant | 2,800,000 | $0 | 6/15/2026 |
| Cruickshank Tim | ▲ Buy | Open Market | 31,250 | $25K | 4/16/2026 |
| Elfrink Willhem | ▲ Buy | Open Market | 187,500 | $150K | 4/16/2026 |
| JAFF MICHAEL R | ▲ Buy | Open Market | 31,250 | $25K | 4/16/2026 |
| Vajdic Branislav | ▲ Buy | Open Market | 31,250 | $25K | 4/16/2026 |
| Richard Ferrari | ▲ Buy | Open Market | 62,500 | $50K | 4/16/2026 |
| ENO Robert Paul | ▲ Buy | Open Market | 12,500 | $10K | 4/16/2026 |
| Ortigas-Wedekind Marga | ▲ Buy | Open Market | 25,000 | $20K | 4/16/2026 |
| STROME MARK E | ▲ Buy | Open Market | 750,000 | $600K | 4/16/2026 |
| Nelson Kenneth Warwick III | ▲ Buy | Grant | 17,241 | $0 | 2/9/2026 |
| JAFF MICHAEL R | ▲ Buy | Grant | 20,689 | $0 | 2/9/2026 |
| Richard Ferrari | ▲ Buy | Grant | 50,000 | $0 | 2/9/2026 |
| de Urioste George | ▼ Sell | Open Market | 33,185 | $94K | 12/18/2025 |
| STROME MARK E | ▼ Sell | Open Market | 250,000 | $895K | 12/17/2025 |
| de Urioste George | ▼ Sell | Open Market | 23,961 | $88K | 12/17/2025 |
| Richard Ferrari | ▲ Buy | Open Market | 29,412 | $50K | 2/14/2025 |
| Cruickshank Tim | ▲ Buy | Open Market | 17,647 | $30K | 2/14/2025 |
| de Urioste George | ▼ Sell | Open Market | 1,674 | $4K | 9/6/2024 |
| de Urioste George | ▼ Sell | Open Market | 5,500 | $13K | 8/30/2024 |
| de Urioste George | ▼ Sell | Open Market | 2,194 | $5K | 8/27/2024 |
| de Urioste George | ▼ Sell | Open Market | 300 | $714 | 8/26/2024 |
| de Urioste George | ▼ Sell | Open Market | 2,500 | $6K | 8/23/2024 |
| Nelson Kenneth Warwick III | ▲ Buy | Grant | 33,185 | $0 | 6/12/2024 |
| Richard Ferrari | ▲ Buy | Grant | 44,247 | $0 | 6/12/2024 |
| Ortigas-Wedekind Marga | ▲ Buy | Grant | 33,185 | $0 | 6/12/2024 |
| JAFF MICHAEL R | ▲ Buy | Grant | 33,185 | $0 | 6/12/2024 |
| Elfrink Willhem | ▲ Buy | Grant | 33,185 | $0 | 6/12/2024 |
| STROME MARK E | ▲ Buy | Grant | 33,185 | $0 | 6/12/2024 |
| de Urioste George | ▲ Buy | Grant | 33,185 | $0 | 6/12/2024 |
| de Urioste George | ▼ Sell | Open Market | 5,500 | $11K | 9/29/2023 |
| de Urioste George | ▼ Sell | Open Market | 8,000 | $16K | 9/28/2023 |
| de Urioste George | ▼ Sell | Open Market | 1,834 | $4K | 9/27/2023 |
| de Urioste George | ▼ Sell | Open Market | 5,000 | $10K | 9/26/2023 |
| de Urioste George | ▼ Sell | Open Market | 2,393 | $5K | 9/22/2023 |
| de Urioste George | ▼ Sell | Open Market | 100 | $241 | 9/21/2023 |
| de Urioste George | ▼ Sell | Open Market | 883 | $2K | 9/20/2023 |
| de Urioste George | ▼ Sell | Open Market | 5,000 | $12K | 9/18/2023 |
| de Urioste George | ▼ Sell | Open Market | 4,269 | $10K | 9/15/2023 |
| de Urioste George | ▼ Sell | Open Market | 5,000 | $11K | 9/14/2023 |
| de Urioste George | ▼ Sell | Open Market | 1,878 | $4K | 9/13/2023 |
| de Urioste George | ▼ Sell | Open Market | 3,122 | $6K | 9/13/2023 |
| STROME MARK E | ▲ Buy | Grant | 23,961 | $0 | 7/13/2023 |
| Richard Ferrari | ▲ Buy | Grant | 31,948 | $0 | 7/13/2023 |
| de Urioste George | ▲ Buy | Grant | 23,961 | $0 | 7/13/2023 |
| Ortigas-Wedekind Marga | ▲ Buy | Grant | 23,961 | $0 | 7/13/2023 |
| Nelson Kenneth Warwick III | ▲ Buy | Grant | 23,961 | $0 | 7/13/2023 |
| Elfrink Willhem | ▲ Buy | Grant | 23,961 | $0 | 7/13/2023 |
| Vajdic Branislav | ▲ Buy | Option Exercise | 1,287 | $0 | 2/10/2023 |
| BROUNSTEIN RICHARD D | ▲ Buy | Option Exercise | 184 | $0 | 2/10/2023 |
| Elfrink Willhem | ▼ Sell | Other | 3,640 | $10K | 2/9/2023 |
| Elfrink Willhem | ▼ Sell | Other | 125,351 | $0 | 2/9/2023 |
| BROUNSTEIN RICHARD D | ▲ Buy | Option Exercise | 760 | $0 | 12/2/2022 |
| BROUNSTEIN RICHARD D | ▲ Buy | Option Exercise | 759 | $0 | 11/2/2022 |
| BROUNSTEIN RICHARD D | ▲ Buy | Option Exercise | 760 | $0 | 10/2/2022 |
| BROUNSTEIN RICHARD D | ▲ Buy | Option Exercise | 757 | $0 | 9/2/2022 |
| BROUNSTEIN RICHARD D | ▲ Buy | Option Exercise | 757 | $0 | 8/1/2022 |
| de Urioste George | ▲ Buy | Grant | 55,147 | $0 | 7/15/2022 |
| Richard Ferrari | ▲ Buy | Grant | 73,529 | $0 | 7/15/2022 |
| Ortigas-Wedekind Marga | ▲ Buy | Grant | 55,147 | $0 | 7/15/2022 |
| Elfrink Willhem | ▲ Buy | Grant | 55,147 | $0 | 7/15/2022 |
| BROUNSTEIN RICHARD D | ▲ Buy | Option Exercise | 757 | $984 | 7/5/2022 |
| BROUNSTEIN RICHARD D | ▲ Buy | Option Exercise | 757 | $0 | 6/2/2022 |
| BROUNSTEIN RICHARD D | ▲ Buy | Option Exercise | 757 | $0 | 5/2/2022 |
| BROUNSTEIN RICHARD D | ▲ Buy | Grant | 757 | $0 | 4/4/2022 |
| BROUNSTEIN RICHARD D | ▲ Buy | Option Exercise | 757 | $0 | 3/2/2022 |
| BROUNSTEIN RICHARD D | ▲ Buy | Grant | 757 | $0 | 2/2/2022 |
| BROUNSTEIN RICHARD D | ▲ Buy | Option Exercise | 1,514 | $0 | 1/2/2022 |
| BROUNSTEIN RICHARD D | ▲ Buy | Open Market | 5,000 | $17K | 12/21/2021 |
| BROUNSTEIN RICHARD D | ▲ Buy | Option Exercise | 19,465 | $82K | 11/11/2021 |
| BROUNSTEIN RICHARD D | ▲ Buy | Option Exercise | 9,732 | $41K | 11/11/2021 |
| BROUNSTEIN RICHARD D | ▲ Buy | Open Market | 5,000 | $30K | 11/11/2021 |
| Ortigas-Wedekind Marga | ▲ Buy | Option Exercise | 7,824 | $33K | 11/11/2021 |
| Ortigas-Wedekind Marga | ▲ Buy | Open Market | 9,000 | $54K | 11/11/2021 |
| Richard Ferrari | ▲ Buy | Option Exercise | 65,653 | $276K | 11/11/2021 |
| Vajdic Branislav | ▲ Buy | Option Exercise | 115,559 | $485K | 11/11/2021 |
| Hunt Jon Patrick | ▲ Buy | Option Exercise | 23,976 | $101K | 11/11/2021 |
| Elfrink Willhem | ▲ Buy | Option Exercise | 60,972 | $256K | 11/11/2021 |
| Elfrink Willhem | ▲ Buy | Option Exercise | 106,825 | $449K | 11/11/2021 |
| Elfrink Willhem | ▲ Buy | Option Exercise | 164,610 | $691K | 11/11/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
HeartBeam Receives FDA Breakthrough Designation for Heart Attack Test
HeartBeam Inc. announced that its Home Heart Attack Test system has been granted FDA Breakthrough Device designation. The designation recognizes the product’s potential to improve early detection of heart attacks at home. The company’s technology could expand its market presence and support future regulatory approvals. The news adds to the company’s positive momentum amid a mixed market session.
HeartBeam Receives FDA Breakthrough Designation for Heart Attack Test. HeartBeam Inc. announced that its Home Heart Attack Test system has been granted FDA Breakthrough Device designation. The designation recognizes the product’s potential to improve early detection of heart attacks at home. The company’s technology could expand its market presence and support future regulatory approvals. The news adds to the company’s positive momentum amid a mixed market session.